komzifti
Generic: ziftomenib·Code: ziftomenib
komzifti: developed by 1 company · 2 FDA decisions. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Kura Oncology, Inc. (KURA) | Approved |
FDA Decisions
FDA_MeetingSuccessful interactions with the FDA regarding the design of two independently powered, randomized, double-blind, placebo-controlled, registrational Phase 3 trials.(KURA)
Approval1 INDICATIONS AND USAGE KOMZIFTI is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment options [see Dosage and Administration ( 2.1 ), Clinical Pharmacology ( 12.1 ), and Clinical Studies ( 14 )] . KOMZIFTI is a menin inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptibl(KURA)
Frequently asked questions
Who is developing komzifti?
komzifti is being developed by Kura Oncology, Inc..
What is komzifti's latest FDA decision?
The most recent tracked FDA decision for komzifti is FDA_Meeting for Successful interactions with the FDA regarding the design of two independently powered, randomized, double-blind, placebo-controlled, registrational Phase 3 trials..
Get deeper analysis on komzifti
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis